NEW YORK (GenomeWeb News) – Oxford Nanopore Technologies said today in its annual report that a commercialization agreement it had with Illumina will terminate on June 30, 2016.

The decision is the outcome of an arbitration demand that Illumina brought against Oxford Nanopore in 2011 over the terms of the agreement. The two firms dismissed the suit in April and agreed to amend the commercialization deal, according to Oxford's annual report.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Technology Review reports that researchers in the US have used CRISPR to modify a number of human embryos.

Plant researchers plan to sequence some 10,000 samples that represent the major plant clades, ScienceInsider reports.

By introducing genes from butterfly peas and Canterbury bells, researchers in Japan have developed a blue chrysanthemum, according to NPR.

In Nature this week: a Danish reference genome, and more.